Zoetis (ZTS) : Traders are bullish on Zoetis (ZTS) as it has outperformed the S&P 500 by a wide margin of 2.5% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.92%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.43% in the last 1 week, and is up 6.98% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.48% and the 50-Day Moving Average is 5.04%.
Zoetis (NYSE:ZTS): The stock opened at $50.08 on Friday but the bulls could not build on the opening and the stock topped out at $50.27 for the day. The stock traded down to $49.52 during the day, due to lack of any buying support eventually closed down at $49.68 with a loss of -0.60% for the day. The stock had closed at $49.98 on the previous day. The total traded volume was 2,089,057 shares.
The company Insiders own 0.05% of Zoetis shares according to the proxy statements. Institutional Investors own 93.72% of Zoetis shares.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.